This Article Full Text Full Text (PDF) All Versions of this Article: 22/11/1865    most recent 01.ATV.0000033821.96354.90v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sternik, L. Articles by Lerman, A. Search for Related Content PubMed PubMed Citation Articles by Sternik, L. Articles by Lerman, A. Related Collections Risk Factors Ion channels/membrane transport Endothelium/vascular type/nitric oxide Other Vascular biology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1865.)
© 2002 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

C-Reactive Protein Relaxes Human Vessels In Vitro

Leonid Sternik; Saquib Samee; Hartzel V. Schaff; Kenton J. Zehr; Lilach O. Lerman; David R. Holmes; Joerg Herrmann; Amir Lerman

From the Division of Cardiovascular Surgery (L.S., H.V.S., K.J.Z.), the Division of Cardiovascular Diseases (S.S., D.R.H., J.H., A.L.), and the Division of Hypertension (L.O.L.), Mayo Clinic and the Mayo Foundation, Rochester, Minn.

Correspondence to Amir Lerman, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail lerman.amir{at}mayo.edu

Objective— C-reactive protein (CRP) is a sensitive marker of inflammation and a prognostic marker in cardiovascular disease. Evidence suggests direct biological activities of CRP within the vascular wall. The study was designed to examine the vasoreactive effects of CRP.

Methods and Results— Human internal mammary artery rings were obtained during cardiovascular bypass surgery and suspended in an organ bath chamber. The rings were precontracted with endothelin-1, and response to cumulative concentrations of CRP was obtained. Experiments were repeated after initial incubation with 20, 40, and 60 mmol/L KCl, the potassium channel blockers BaCl, tetraethylammonium chloride, and glibenclamide, and the NO synthase inhibitor N-monomethyl-L-arginine and also after removal of the endothelium. CRP caused dose-dependent relaxation of human internal mammary artery rings, which was not affected by preincubation with N-monomethyl-L-arginine or removal of the endothelium. Maximum relaxation response to CRP (79.5±10%) was attenuated by KCl (2.5±11.5%, P<0.001), BaCl (24.5±7.5%, P<0.001), and tetraethylammonium chloride (34.9±8.25%, P<0.01) but not by glibenclamide.

Conclusions– The present study demonstrates that CRP exerts an endothelium-independent vasorelaxing effect via potassium channels. Thus, the study suggests a role of CRP in the regulation of vascular tone.

Key Words: atherosclerosis • C-reactive protein • potassium channels • vasorelaxation • inflammation

This article has been cited by other articles:

				D. N. Patel, C. A. King, S. R. Bailey, J. W. Holt, K. Venkatachalam, A. Agrawal, A. J. Valente, and B. Chandrasekar Interleukin-17 Stimulates C-reactive Protein Expression in Hepatocytes and Smooth Muscle Cells via p38 MAPK and ERK1/2-dependent NF-{kappa}B and C/EBPbeta Activation J. Biol. Chem., September 14, 2007; 282(37): 27229 - 27238. [Abstract] [Full Text] [PDF]

				H. Teoh, A. Quan, and S. Verma Does C-reactive protein predict saphenous vein graft patency? J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 277 - 279. [Full Text] [PDF]

				E. Grad, M. Golomb, I. Mor-Yosef, N. Koroukhov, C. Lotan, E. R. Edelman, and H. D. Danenberg Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H489 - H495. [Abstract] [Full Text] [PDF]

				T. Yoshida, T. Kaneshi, T. Shimabukuro, M. Sunagawa, and T. Ohta Serum C-Reactive Protein and Its Relation to Cardiovascular Risk Factors and Adipocytokines in Japanese Children J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2133 - 2137. [Abstract] [Full Text] [PDF]

				M. Hermann and F. Ruschitzka Novel anti-inflammatory drugs in hypertension Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864. [Full Text] [PDF]

				S. B. Schwedler, K. Amann, K. Wernicke, A. Krebs, M. Nauck, C. Wanner, L. A. Potempa, and J. Galle Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E-Knockout Mice Circulation, August 16, 2005; 112(7): 1016 - 1023. [Abstract] [Full Text] [PDF]

				K. E. Taylor, J. C. Giddings, and C. W. van den Berg C-Reactive Protein-Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1225 - 1230. [Abstract] [Full Text] [PDF]

				A. N. Swafford Jr., I. N. Bratz, J. D. Knudson, P. A. Rogers, J. M. Timmerman, J. D. Tune, and G. M. Dick C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1786 - H1795. [Abstract] [Full Text] [PDF]

				B. R. Clapp, G. M. Hirschfield, C. Storry, J. R. Gallimore, R. P. Stidwill, M. Singer, J. E. Deanfield, R. J. MacAllister, M. B. Pepys, P. Vallance, et al. Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability Circulation, March 29, 2005; 111(12): 1530 - 1536. [Abstract] [Full Text] [PDF]

				Y. Ivashchenko, F. Kramer, S. Schafer, A. Bucher, K. Veit, V. Hombach, A. Busch, O. Ritzeler, J. Dedio, and J. Torzewski Protein Kinase C Pathway Is Involved in Transcriptional Regulation of C-Reactive Protein Synthesis in Human Hepatocytes Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 186 - 192. [Abstract] [Full Text] [PDF]

				C. W. van den Berg, K. E. Taylor, and D. Lang C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): e168 - e171. [Abstract] [Full Text] [PDF]

				P. Bogaty, J. M. Brophy, M. Noel, L. Boyer, S. Simard, F. Bertrand, and G. R. Dagenais Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study Circulation, August 24, 2004; 110(8): 934 - 939. [Abstract] [Full Text] [PDF]

				A. Paul, K. W.S. Ko, L. Li, V. Yechoor, M. A. McCrory, A. J. Szalai, and L. Chan C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, February 10, 2004; 109(5): 647 - 655. [Abstract] [Full Text] [PDF]

				S. B. Schwedler, F. Guderian, J. Dammrich, L. A. Potempa, and C. Wanner Tubular staining of modified C-reactive protein in diabetic chronic kidney disease Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2300 - 2307. [Abstract] [Full Text] [PDF]